These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19165235)

  • 1. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Marchal S; Galenne T; Juin P; Becuwe P; Merlin JL
    Cancer Gene Ther; 2009 Jun; 16(6):498-507. PubMed ID: 19165235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells.
    Li X; Luwor R; Lu Y; Liang K; Fan Z
    Oncogene; 2006 Jan; 25(4):525-35. PubMed ID: 16170346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
    Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
    Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
    Shankar S; Srivastava RK
    Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells.
    Dhupkar P; Dowling M; Cengel K; Chen B
    Anticancer Res; 2010 Jun; 30(6):1905-10. PubMed ID: 20651333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of tumor suppressor protein PTEN and induction of apoptosis are involved in cAMP-mediated inhibition of cell number in B92 glial cells.
    Sugimoto N; Miwa S; Ohno-Shosaku T; Tsuchiya H; Hitomi Y; Nakamura H; Tomita K; Yachie A; Koizumi S
    Neurosci Lett; 2011 Jun; 497(1):55-9. PubMed ID: 21529704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
    Liu X; Guo WJ; Zhang XW; Cai X; Tian S; Li J
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):871-8. PubMed ID: 21286718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.
    Zuo Q; Shi M; Li L; Chen J; Luo R
    Biomed Pharmacother; 2010 Oct; 64(8):550-8. PubMed ID: 20630698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
    Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
    Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation through interaction with EGFR and PTEN.
    Zheng J; Dai Y; Yang Z; Yang L; Peng Z; Meng R; Xiong Y; He J
    Oncol Rep; 2016 Jan; 35(1):530-7. PubMed ID: 26531778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab.
    Jing Z; Gong L; Xie CY; Zhang L; Su HF; Deng X; Wu SX
    Radiother Oncol; 2009 Dec; 93(3):468-73. PubMed ID: 19744737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction.
    Tang Y; Eng C
    Cancer Res; 2006 Jun; 66(12):6139-48. PubMed ID: 16778187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
    Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
    Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis.
    Brouxhon SM; Kyrkanides S; Raja V; Silberfeld A; Teng X; Trochesset D; Cohen J; Ma L
    Mol Cancer Ther; 2014 Jul; 13(7):1791-802. PubMed ID: 24748654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.